MARCH 6th - One year ago on this day, I found out I had cancer and also had surgery to remove it. A colonoscopy found a 6 cm tumor that was causing intussusception (a telescoping of the colon) that had only started causing unbearable pain just a few days earlier. I had not experienced any other typical symptoms of colon cancer before that. I had a right hemi-colectomy, removing half of my colon and over 30 lymph nodes. Pathology revealed that while I was Stage 2, there were some high risk features of my tumor. I had a high rate of “tumor budding”. This means tiny clusters of cancer cells were breaking away and invading nearby tissue. Anything above 10 is considered “high” and I was at 13. There was also the beginning of vascular invasion. These features increased my chance of having a recurrence by 1.5 to 2x and necessitated that I do adjuvant treatment to prevent a recurrence. I was so very fortunate to find @ImmunityBio and @DrPatrick early on and am so grateful that I was able to do their incredible BIOSHIELD protocol. I received ANKTIVA and a targeted immunotherapy injection (ETBX-011) that trained my immune system to recognize and attack any colon cancer cells expressing the CEA marker. I also took oral chemo pills that acted as an immunomodulator that made any possible remaining cancer easier for the immune system to recognize. This treatment is innovative, targeted, personalized and I believe GAME CHANGING. I hope and pray that the @US_FDA and others (@DrMakaryFDA, @DrJBhattacharya, @RobertKennedyJr) realize what they have right in front of them. Let’s save the people that need it and then help people restore and preserve their immune systems so we don’t HAVE desperate stage 4 patients anymore. While the one year milestone is great, 80% of recurrences occur within the first 2-3 years after surgery. The highest risk window is the first 18-24 months. I am in surveillance mode but I know that my immune system is ACTIVATED, ROBUST, TRAINED and on HIGH ALERT. I plan on making this same post again next year on March 6th! #Cancer #ColonCancer #ANKTIVA #BIOSHIELD #ImmunityBio $IBRX

Last week’s CT Scan 🔥‼️All Clear‼️🔥 Still CANCER FREE thanks to #Anktiva helping my immune system do what it’s supposed to do! Now I get to do what I love to do and I’m not planning on stopping anytime soon. (And yes this last lift of our session was UGLY🫣). #cancerfree #CrossFit $IBRX @ImmunityBio

$IBRX ANKTIVA (N-803) should be considered for inclusion iin the Commissioner’s National Priority Voucher pilot program, shifting the paradigm from tumor-specific targeting to a pan-tumor immune-reconstitution strategy. Please write a comment on stkt.co/G5KnZ4n3

If you missed the FDA hearing about the Commissioner’s National Priority Voucher Program where @LoriMills4CA42 I gave comments, here is what I said: Good afternoon, distinguished panelists and members of the FDA. As Henry Ford said: “We need a faster horse.”  My name is Karol Hansen. I am a Stage IV breast cancer patient with Mets to the bones. I have been fighting cancer for 10 years. In that time, I have undergone chemotherapy twice, radiation three times, and more than 25 surgeries. The cancer has recurred over 11 times. 10 years ago, Nuelasta was prescribed to me before I even had neutropenia because it’s medically known that chemotherapy causes Netropenia. Neutrophils are an inherent part of the body’s immune system that provide rapid, broad, innate protection against infection and injury. Lymphocytes form the core of the adaptive immune system and are responsible for precise, targeted and long-lasting immunity. Neulasta, and its biosimilars, is given prophylactically to protect neutrophils. ANK TIVA, manufactured by Immunity Bio in California protects lymphocytes, but it is NOT YET approved by the FDA for all cancer types. During these years of relentless treatment my Absolute Lymphocyte Count remains critically low — below the threshold associated with increased infections, weakness, treatment failure, and shortened survival. There are millions of cancer patients whose ALC looks just like mine. RIGHT NOW, at the Chan Soon-Shiong Institute for Medicine there are 15,000 patients waiting in line to receive ANK TIVA. ANK TIVA is the first therapy designed to restore and activate lymphocytes through its IL-15 mechanism. It is the missing piece of immune boosting protection — ANK TIVA is the equivalent to lymphocytes as Neulasta is to neutrophils. I have intractable, treatment-resistant cancer that has failed standard therapies. If ANK TIVA had been available as standard supportive care a decade ago, I might have been spared years of immune collapse, repeated recurrences, and the physical and emotional toll of more than 25 surgeries. Now I am out of time, out of strength and out of options. The 15,000 patients waiting for ANK TIVA can only get it if an opening is available in a narrow group of clinical trials or through the Extended Access Program, which the clinic has to process one at a time, on a case by case basis. A VERY SLOW process. It took almost a year for me to get approved. That’s not POLITICS, that’s imminent death for critically ill patients. Ladies and gentlemen, we HAVE the cart, which is ANK TIVA. But, as Henry Ford said, “WE NEED A FASTER HORSE!”  The Commissioner’s National Priority Voucher Program IS THAT FASTER HORSE!  Immunity Bio is delivering groundbreaking immune-restoring therapy of ANK TIVA but the FDA needs to approve it as a first line of defense for patients with lymphopenia.  The CNPV Program was created to accelerate exactly these kinds of innovative therapies that address critical unmet needs and can transform patient outcomes. I urge the FDA to prioritize ANK TIVA for full approval and label expansion so that every cancer patient undergoing chemotherapy or radiation can receive lymphocyte support proactively — not as a desperate final measure after years of fighting for survival. It is TIME for a faster horse at the FDA. Streamline the review process. Provide a patient conduit directly to CNPV. Give us a voice. Speed up access to ANK TIVA. Give future patients the CHANCE at a fuller life that I, and others who have died while waiting, have been denied. Thank you for listening to my story and for the work you do every day on behalf of patients like me

I’ll be speaking tomorrow in front of the FDA to advocate for ANKTIVA to be given to all cancer patients as a first line of defense. If you’re interested in this hearing discussing the Commissioner’s National Priority Voucher Program you can watch the hearing on their YouTube channel starting at 1:00 pm Eastern: youtube.com/live/5gS9gJ99Cvk… Approve Anktiva! @LoriMills4CA42 @DrPatrick @richadcock @ImmunityBio @ChiayuChenMD @bullishbruk @USNCG5Rick @tteuscher @GretchMick @Brandon_r_clark @CarnivoreKen @JeffRoseTV @theduffhoneybee @ethan_leffler @Natasha_Buga @megbasham @reborn_amit @shelbysaidthat @Kathryn83970251 @SandyGl88167783

$IBRX Dr. Pat interview. Worth watching. youtu.be/MAaEG7YP_m0

FDA is holding up approval for Dr. Soon Shiong's Anktiva for papillary bladder cancer. Take a minute to look at the cancer-free statistics from ChatGPT for Merck's Keytruda, which was approved for papillary bladder cancer, vs Anktiva, which has yet to be approved for papillary bladder cancer, despite the fact that Anktiva is the superior drug for this disease. At 24 months: Keytruda: ~30–40% disease-free. Anktiva BCG ~52% disease-free. At 3 years: 73% of Keytruda patients kept their bladders. 82% of Anktiva BCG patients kept their bladders. At 3 years: Keytruda overall survival: ~90% Anktiva BCG overall survival: ~96% Dr. Makary, Dr. Bhattacharya, Sec Kennedy, please do the right thing and approve Anktiva for papillary bladder cancer now. Save more lives. Please help spread the word & retweet this post. @DrMakaryFDA @DrPatrick @ImmunityBio @DrJBhattacharya @ChrisCuomo @SecKennedy @LoriMills4CA42 @tteuscher @CarnivoreKen @julie_bush @bullishbruk @exosome @Johnincarlisle @chrisca70578779

My husband was diagnosed with glioblastoma and given 12 months to live. He has been on #ANKTIVA and PDL-1 NK infusions. He has now had 2 normal brain scans. The red tape to ground breaking therapy needs to be cut! The fact the FDA wrote Dr Pat a letter to silence him is a disgrace. People deserve to choose the path that makes sense to them. They deserve hope! They shouldn’t have to fail standard therapy to be given a chance at life. The first MRI is before, the 2nd after. @bullishbruk

Feeling grateful to be healthy and still cancer free on my 56th birthday. So I thought I’d do 56 deadlifts. 🙃 Thanks to my great doctors in Cleveland and my @immunitybio team and @DrPatrick. #ANKTIVA #coloncancer #ALC $IBRX @crossfitwillpower

$IBRX A billionaire in his 70s still grinding every day not for headlines, but to push forward treatments for ALC and cancer. He’s taking on big pharma, challenging the system, and staying directly connected to patients sometimes even responding personally to those reaching out for help. That kind of commitment is rare. This isn’t about money it’s about impact, purpose, and changing lives.

March is Colorectal Cancer Awareness Month. As a GI oncologist, there’s something I wish everyone understood: Many of the patients I see with colon cancer never thought they were at risk. Some are in their 40s. Some even younger. Here’s what everyone should know 👇

This woman got beaten up by ‘biological male’ Imane Khelif. Her Olympics dreams were crushed. Liberal activists defended a man beating her up. She deserves an apology.

Dr. Patrick is a polymath and N of 1 biotech pioneer. He is relentless and won’t stop until Immunity Bio makes a huge dent in cancer care. @DrPatrick wsj.com/business/media/the-s…

"You’re too young for that" is a phrase that's becoming dangerously outdated in medicine. From colon cancer to breast cancer, the age of onset is dropping, and the aggressiveness is rising. Don't wait for "standard" screening ages if you feel something is wrong. You are your own best advocate. @DrKellyVictory

According to a new study, people who took last winter's flu vaccine were 26.9% more likely to get influenza than the unvaccinated.

Chemotherapy kills cancer cells. It also kills the immune cells that kill cancer cells. Most of oncology has accepted that trade-off. @DrPatrick never did. He built Anktiva, an IL-15 agonist that activates and expands your NK cells and T cells without triggering the suppressive cells that protect tumors. Saudi Arabia just approved it for lung cancer. First country in the world to do so. I've been using IL-15 intratumorally in combination with other immunotherapy agents for years. What Dr. Soon-Shiong is doing at the systemic level, we're doing at the tumor level. The future of cancer treatment isn't about finding better poisons. It's about unlocking what's already inside you.

Dr. Patrick Soon-Shiong just showed Chris Cuomo dramatic before-and-after brain scans of late-stage tumor patients who failed chemo, radiation, and surgery — achieving complete remission with ANKTIVA. No chemo. No radiation. Tumors shrinking dramatically in months. He says: “We got FDA approval to treat patients who failed everything… and they got complete remissions. It wasn’t a one-off anecdote.” ANKTIVA (nogapendekin alfa inbakicept) is an IL-15 superagonist that activates and proliferates natural killer cells and CD8 T-cells while avoiding regulatory T-cell suppression, turning the immune system into a targeted cancer-killing force. Clip from this 43-second segment — a potential game-changer for late-stage cases. Is ANKTIVA the breakthrough we’ve been waiting for… or do we need larger trials to confirm? Your thoughts — drop them below. Stay informed. Stay hopeful.

Hmmm 🤔 … looking forward to hearing this.